Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ninjin'yoeito plus anamorelin for cancer cachexia in gastrointestinal cancers (phase II, randomized)
jRCTs051250121Phase 2Recruiting
- Sponsor
- Kracie
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastric cancer (GC), pancreatic cancer (PC), colorectal cancer (CRC) and 2 more comparing Anamorelin monotherapy with Anamorelin plus Ninjin'yoeito (2 arms). Primary endpoint: Change in Cancer Fatigue Scale score at 4 weeks. Started Jan 2026; status: recruiting.
02
Drugs
anamorelinninjinyoeito
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)colorectal cancer (CRC)cancer anorexia-cachexia syndrome (CACS)cancer-related fatigue (CRF)
Beyond the preview
Go deeper on jRCTs051250121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250121.